HER-2/neu detection in fine-needle aspirates of breast cancer - Fluorescence in situ hybridization and immunocytochemical analysis

被引:59
作者
Beatty, BG
Bryant, R
Wang, WC
Ashikaga, T
Gibson, PC
Leiman, G
Weaver, DL
机构
[1] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
[2] Univ Vermont, Coll Med, Dept Biostat, Burlington, VT 05405 USA
[3] Vermont Reg Canc Ctr, Burlington, VT USA
关键词
HER-2/neu; breast cancer; fine-needle aspirate; immunocytochemistry; immunohistochemistry; fluorescence in situ hybridization;
D O I
10.1309/X8UP920UF4XM1C5C
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We evaluated HER-2 receptor status by immunocytochemical and immunohistochemical analyses and fluorescence in situ hybridization (FISH) in 51 fine-needle aspiration (FNA) specimens together with the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from surgically resected breast cancers. Three fixation methods were compared ethanol, formalin, and CytoLyt-ThinPrep (Cytyc, Boxborough, MA). HER-2 was overexpressed and amplified in 8 (16%) of 51 FFPE specimens. Of the 8 cases, gene amplification was observed in 8 FNA specimens (100%) and overexpression in 2 (25%) ethanol-, 4 (50%) CytoLyt-, and 5 (63%)formalin-fixed FNA specimens. Strong pairwise kappa association between FISH results performed on FNA specimens and FFPE tissue samples (ethanol fixation, kappa = 0.848; ThinPrep, kappa = 0.918) and moderate (ThinPrep, kappa = 0.692; formalin fixation, kappa = 0.667) to poor (ethanol, kappa = 0.300) pairwise kappa agreement between tissue immunohistochemical and FNA immunocytochemical results was demonstrated. We conclude that HER-2 protein expression on cytologic preparations was insufficiently reliable for clinical use, whereas HER-2 gene amplification determined by FISH demonstrated strong and consistent correlation with HER-2 status of FFPE tissue samples.
引用
收藏
页码:246 / 255
页数:10
相关论文
共 46 条
[31]   Evaluation of HER-2/neu gene amplification and overexpression:: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens [J].
Press, MF ;
Slamon, DJ ;
Flom, KJ ;
Park, J ;
Zhou, JY ;
Bernstein, L .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) :3095-3105
[32]   HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas [J].
Press, MF ;
Bernstein, L ;
Thomas, PA ;
Meisner, LF ;
Zhou, JY ;
Ma, YL ;
Hung, G ;
Robinson, RA ;
Harris, C ;
ElNaggar, A ;
Slamon, DJ ;
Phillips, RN ;
Ross, JS ;
Wolman, SR ;
Flom, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2894-2904
[33]  
PRESS MF, 1993, CANCER RES, V53, P4960
[34]   ERBB2 oncogene in human breast cancer and its clinical significance [J].
Révillion, F ;
Bonneterre, J ;
Peyrat, JP .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) :791-808
[35]   PROGNOSTIC-SIGNIFICANCE OF HER-2-NEU EXPRESSION IN BREAST-CANCER AND ITS RELATIONSHIP TO OTHER PROGNOSTIC FACTORS [J].
RILKE, F ;
COLNAGHI, MI ;
CASCINELLI, N ;
ANDREOLA, S ;
BALDINI, MT ;
BUFALINO, R ;
DELLAPORTA, G ;
MENARD, S ;
PIEROTTI, MA ;
TESTORI, A .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (01) :44-49
[36]   The HER-2/neu oncogene:: prognostic factor, predictive factor and target for therapy [J].
Ross, JS ;
Fletcher, JA .
SEMINARS IN CANCER BIOLOGY, 1999, 9 (02) :125-138
[37]   Fluorescence in situ hybridization for detecting ErbB-2 amplification in breast tumor fine needle aspiration biopsies [J].
Sauter, G ;
Feichter, G ;
Torhorst, J ;
Moch, H ;
Novotna, H ;
Wagner, U ;
Durmuller, U ;
Waldman, FM .
ACTA CYTOLOGICA, 1996, 40 (02) :164-173
[38]  
Shimizu C, 2000, J SURG ONCOL, V73, P17, DOI 10.1002/(SICI)1096-9098(200001)73:1<17::AID-JSO5>3.0.CO
[39]  
2-2
[40]   STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER [J].
SLAMON, DJ ;
GODOLPHIN, W ;
JONES, LA ;
HOLT, JA ;
WONG, SG ;
KEITH, DE ;
LEVIN, WJ ;
STUART, SG ;
UDOVE, J ;
ULLRICH, A ;
PRESS, MF .
SCIENCE, 1989, 244 (4905) :707-712